MCID: VRL017
MIFTS: 35

Viral Hemorrhagic Fever

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Viral Hemorrhagic Fever

Summaries for Viral Hemorrhagic Fever

CDC : 3 VHFs are caused by viruses of five distinct families: Arenaviridae, Bunyaviridae, Filoviridae, Flaviviridae, and Paramyxoviridae. Each of these families share a number of features:

MalaCards based summary : Viral Hemorrhagic Fever, also known as hemorrhagic fevers, viral, is related to hemorrhagic fever and lassa fever, and has symptoms including gingival bleeding, hearing impairment and epistaxis. An important gene associated with Viral Hemorrhagic Fever is LBR (Lamin B Receptor). The drugs Benzocaine and Menthol have been mentioned in the context of this disorder. Affiliated tissues include testes, endothelial and t cells.

Wikipedia : 72 Viral hemorrhagic fevers (VHFs) are a diverse group of animal and human illnesses in which fever and... more...

Related Diseases for Viral Hemorrhagic Fever

Diseases in the Hemorrhagic Fever family:

Viral Hemorrhagic Fever

Diseases related to Viral Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 13)
id Related Disease Score Top Affiliating Genes
1 hemorrhagic fever 11.3
2 lassa fever 11.2
3 dengue disease 11.0
4 kyasanur forest disease 10.9
5 capillary leak syndrome 10.9
6 ebola hemorrhagic fever 10.9
7 marburg hemorrhagic fever 10.9
8 omsk hemorrhagic fever 10.9
9 hantavirus pulmonary syndrome 9.9
10 hemorrhagic fever with renal syndrome 9.8
11 rift valley fever 9.8
12 thrombocytopenia 9.7
13 vascular disease 9.7

Graphical network of the top 20 diseases related to Viral Hemorrhagic Fever:



Diseases related to Viral Hemorrhagic Fever

Symptoms & Phenotypes for Viral Hemorrhagic Fever

Human phenotypes related to Viral Hemorrhagic Fever:

32 (show all 24)
id Description HPO Frequency HPO Source Accession
1 gingival bleeding 32 frequent (33%) HP:0000225
2 hearing impairment 32 occasional (7.5%) HP:0000365
3 epistaxis 32 frequent (33%) HP:0000421
4 skin rash 32 frequent (33%) HP:0000988
5 seizures 32 occasional (7.5%) HP:0001250
6 decreased liver function 32 frequent (33%) HP:0001410
7 thrombocytopenia 32 frequent (33%) HP:0001873
8 leukopenia 32 frequent (33%) HP:0001882
9 subcutaneous hemorrhage 32 frequent (33%) HP:0001933
10 fever 32 hallmark (90%) HP:0001945
11 diarrhea 32 frequent (33%) HP:0002014
12 nausea and vomiting 32 frequent (33%) HP:0002017
13 abdominal pain 32 frequent (33%) HP:0002027
14 migraine 32 frequent (33%) HP:0002076
15 gastrointestinal hemorrhage 32 frequent (33%) HP:0002239
16 encephalitis 32 occasional (7.5%) HP:0002383
17 arthralgia 32 frequent (33%) HP:0002829
18 myalgia 32 frequent (33%) HP:0003326
19 reduced consciousness/confusion 32 occasional (7.5%) HP:0004372
20 spontaneous abortion 32 frequent (33%) HP:0005268
21 fatigue 32 hallmark (90%) HP:0012378
22 recurrent bronchiolitis 32 occasional (7.5%) HP:0100501
23 retrobulbar optic neuritis 32 occasional (7.5%) HP:0100654
24 chest pain 32 frequent (33%) HP:0100749

UMLS symptoms related to Viral Hemorrhagic Fever:


fever, pruritus

Drugs & Therapeutics for Viral Hemorrhagic Fever

Drugs for Viral Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 119)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
2
Menthol Approved Phase 4 2216-51-5 16666
3
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
4
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
5 tannic acid Approved, Nutraceutical Phase 4,Phase 1,Phase 2
6 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
7 Dermatologic Agents Phase 4,Phase 1,Phase 2
8 Vasoconstrictor Agents Phase 4
9 Anti-Allergic Agents Phase 4
10 Antipruritics Phase 4
11 Histamine Antagonists Phase 4
12 Histamine H1 Antagonists Phase 4
13
Histamine Phosphate Phase 4 51-74-1 65513
14 Neurotransmitter Agents Phase 4
15
Ivermectin Approved, Vet_approved Phase 2, Phase 3 70288-86-7 6474909 46936176
16
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
17
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 11103-57-4, 68-26-8 445354
18
Lactitol Investigational Phase 3 585-86-4 3871
19 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
20 Anti-Infective Agents Phase 2, Phase 3, Phase 1
21 Antiparasitic Agents Phase 2, Phase 3,Phase 1
22 DEET Phase 3
23 Insect Repellents Phase 3
24 Protective Agents Phase 3,Phase 1
25 Antibodies Phase 3,Phase 1,Phase 2
26 Immunoglobulins Phase 3,Phase 1,Phase 2
27 Antibodies, Blocking Phase 3
28 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
29 Krestin Phase 3,Phase 2,Phase 1
30 Vitamins Phase 3,Phase 2
31 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
32 Iron-Dextran Complex Phase 3
33 Antioxidants Phase 3
34 Micronutrients Phase 3
35 Retinol palmitate Phase 3
36 Trace Elements Phase 3
37 retinol Nutraceutical Phase 3
38
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
39
Ribavirin Approved Phase 2 36791-04-5 37542
40
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 53477736 447043
41
Coal tar Approved Phase 1, Phase 2 8007-45-2
42
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
43
Sunitinib Approved, Investigational Phase 1, Phase 2 341031-54-7, 557795-19-4 5329102
44
chloroquine Approved, Vet_approved Phase 1, Phase 2 54-05-7 2719
45
Artemether Approved Phase 2 71963-77-4 119380 68911
46
Lumefantrine Approved Phase 2 82186-77-4 6437380
47
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
48
Epinephrine Approved, Vet_approved Phase 2,Phase 1 51-43-4 5816
49 Racepinephrine Approved Phase 2,Phase 1
50
Angiotensin II Investigational Phase 1, Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143

Interventional clinical trials:

(show top 50) (show all 232)

id Name Status NCT ID Phase Drugs
1 High Frequency Ventilation During Off Pump Coronary Artery Bypass Graft (CABG) Completed NCT00863044 Phase 4
2 Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi Recruiting NCT02911415 Phase 4
3 Open Study of the Duration of Immunity After Vaccination With GamEvac Recruiting NCT02911428 Phase 4
4 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Recruiting NCT02673840 Phase 4 Ketotifen;Placebo
5 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Recruiting NCT03072030 Phase 4
6 Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals Recruiting NCT03132311 Phase 4
7 Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study) Recruiting NCT02555072 Phase 4
8 Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE) Not yet recruiting NCT02991495 Phase 4
9 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
10 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
11 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
12 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
13 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
14 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
15 Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS Completed NCT02360514 Phase 3 Hantavax injection
16 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
17 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
18 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
19 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
20 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed NCT01466387 Phase 3
21 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
22 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Recruiting NCT02509494 Phase 3
23 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
24 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
25 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Active, not recruiting NCT01373281 Phase 3
26 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
27 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
28 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
29 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Active, not recruiting NCT01426243 Phase 3
30 Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. Active, not recruiting NCT02699099 Phase 3
31 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Suspended NCT03161366 Phase 3
32 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
33 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
34 Treatment of Japanese Encephalitis Unknown status NCT00216268 Phase 2 Ribavirin
35 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
36 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
37 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
38 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
39 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
40 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
41 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
42 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
43 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
44 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
45 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
46 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
47 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
48 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
49 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
50 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2

Search NIH Clinical Center for Viral Hemorrhagic Fever

Genetic Tests for Viral Hemorrhagic Fever

Anatomical Context for Viral Hemorrhagic Fever

MalaCards organs/tissues related to Viral Hemorrhagic Fever:

39
Testes, Endothelial, T Cells, Liver, Skin, Kidney

Publications for Viral Hemorrhagic Fever

Articles related to Viral Hemorrhagic Fever:

(show top 50) (show all 61)
id Title Authors Year
1
Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses. ( 28194457 )
2017
2
Molecular pathogenesis of viral hemorrhagic fever. ( 28555386 )
2017
3
The Epi Info Viral Hemorrhagic Fever (VHF) Application: A Resource for Outbreak Data Management and Contact Tracing in the 2014-2016 West Africa Ebola Epidemic. ( 27587635 )
2016
4
Systems Pharmacology Uncovers the Multiple Mechanisms of Xijiao Dihuang Decoction for the Treatment of Viral Hemorrhagic Fever. ( 27239215 )
2016
5
Lujo viral hemorrhagic fever: considering diagnostic capacity and preparedness in the wake of recent Ebola and Zika virus outbreaks. ( 27593704 )
2016
6
Hospital Preparations for Viral Hemorrhagic Fever Patients and Experience Gained from Admission of an Ebola Patient. ( 26812146 )
2016
7
HMGB1 Is a Potential Biomarker for Severe Viral Hemorrhagic Fevers. ( 27348219 )
2016
8
Addressing the Complications of Ebola and Other Viral Hemorrhagic Fever Infections: Using Insights from Bacterial and Fungal Sepsis. ( 26425845 )
2015
9
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. ( 26186980 )
2015
10
Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome? ( 26136549 )
2015
11
Viral Hemorrhagic Fever Diagnostics. ( 26354968 )
2015
12
A Multiplex PCR/LDR Assay for the Simultaneous Identification of Category A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and Variola Virus. ( 26381398 )
2015
13
Animal models for some important RNA viruses of public health concern in SEARO countries: Viral hemorrhagic fever. ( 25815861 )
2015
14
Animal models of viral hemorrhagic fever. ( 25448088 )
2014
15
Viral hemorrhagic fever cases in the country of Georgia: Acute Febrile Illness Surveillance Study results. ( 24891463 )
2014
16
Animal Models for Viral Hemorrhagic Fever. ( 24690109 )
2014
17
Diagnostic schemes for reducing epidemic size of African viral hemorrhagic fever outbreaks. ( 25212079 )
2014
18
Simultaneous detection of IgG antibodies associated with viral hemorrhagic fever by a multiplexed Luminex-based immunoassay. ( 24631566 )
2014
19
The pathogenesis of severe Fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic Fever. ( 24257618 )
2014
20
Development and validation of serological assays for viral hemorrhagic fevers and determination of the prevalence of Rift Valley fever in Borno State, Nigeria. ( 25344695 )
2014
21
Viral hemorrhagic fever viruses. ( 24314803 )
2013
22
Outbreak of viral hemorrhagic fever caused by dengue virus type 3 in Al-Mukalla, Yemen. ( 23497142 )
2013
23
Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. ( 23711383 )
2013
24
Alkhurma viral hemorrhagic fever virus: proposed guidelines for detection, prevention, and control in Saudi Arabia. ( 22860139 )
2012
25
Simian hemorrhagic fever virus infection of rhesus macaques as a model of viral hemorrhagic fever: clinical characterization and risk factors for severe disease. ( 22014505 )
2011
26
Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. ( 20846417 )
2010
27
Reappearance of viral hemorrhagic fever with renal syndrome in northwestern Greece. ( 19926507 )
2010
28
Aerosol exposure to the angola strain of marburg virus causes lethal viral hemorrhagic Fever in cynomolgus macaques. ( 20807825 )
2010
29
Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa. ( 21413569 )
2010
30
Gene expression in primate liver during viral hemorrhagic fever. ( 19216742 )
2009
31
Viral hemorrhagic fever-induced acute kidney injury. ( 18620963 )
2008
32
Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers? ( 17897725 )
2007
33
Viral hemorrhagic fever - an ICU perspective. ( 16827967 )
2006
34
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. ( 16704825 )
2006
35
Alkhumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. ( 16038757 )
2005
36
Pathogenesis of viral hemorrhagic fever. ( 15955687 )
2005
37
Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. ( 14978138 )
2004
38
Correction: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. ( 15171793 )
2004
39
Emerging roles of tissue factor in viral hemorrhagic fever. ( 15324737 )
2004
40
Treating viral hemorrhagic fever. ( 14600838 )
2003
41
Implementation of the Canadian contingency plan for a case of suspected viral hemorrhagic fever. ( 12725358 )
2003
42
Viral hemorrhagic fever--a vascular disease? ( 12783108 )
2003
43
Mitogen therapy for biological warfare/terrorist attacks and viral hemorrhagic fever control. ( 11915170 )
2002
44
Viral hemorrhagic fevers including hantavirus pulmonary syndrome in the Americas. ( 12489291 )
2002
45
Viral hemorrhagic fever in Pakistan: awareness among health care personnel. ( 12174494 )
2002
46
False-negative results of PCR assay with plasma of patients with severe viral hemorrhagic fever. ( 12409441 )
2002
47
Viral hemorrhagic fever hazards for travelers in Africa. ( 11595975 )
2001
48
Effects of viral hemorrhagic fever inactivation methods on the performance of rapid diagnostic tests for Plasmodium falciparum. ( 9815250 )
1998
49
Viral hemorrhagic fever: Admission policy for hospitals in the Arabian Peninsula. ( 17341986 )
1998
50
From the Centers for Disease Control and Prevention. Update: outbreak of Ebola viral hemorrhagic fever--Zaire, 1995. ( 7616623 )
1995

Variations for Viral Hemorrhagic Fever

Expression for Viral Hemorrhagic Fever

Search GEO for disease gene expression data for Viral Hemorrhagic Fever.

Pathways for Viral Hemorrhagic Fever

GO Terms for Viral Hemorrhagic Fever

Sources for Viral Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....